This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Skin cancer

BRAF; c-jun N-terminal kinase (JNK)

In vitro and mouse studies suggest the BRAF inhibitor Zelboraf vemurafenib could induce cutaneous squamous cell carcinoma (cSCC) by inhibiting JNK signaling. Treatment of melanoma with BRAF inhibitors can increase the incidence of cSCC. In cSCC cells and keratinocytes, Zelboraf suppressed JNK activation and apoptosis by inhibiting kinases upstream of JNK including sterile a-motif and leucine zipper containing kinase AZK (ZAK). Next steps include using this information to design melanoma therapeutics that do not reduce JNK signaling.
Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd. and Roche market Zelboraf to treat melanoma.
GlaxoSmithKline plc markets the BRAF inhibitor Tafinlar dabrafenib to treat melanoma.
At least four other companies have BRAF inhibitors in Phase III or earlier testing to treat cancers.

SciBX 6(47); doi:10.1038/scibx.2013.1347
Published online Dec. 12, 2013

Patent status not applicable; unavailable for licensing

Vin, H. et al. eLife; published online Nov. 5, 2013;
doi:10.7554/eLife.00969
Contact: Kenneth Y. Tsai, The University of Texas MD Anderson Cancer Center, Houston, Texas
e-mail:
kytsai@mdanderson.org